Investment Thesis
GRI Bio is a pre-revenue stage pharmaceutical company with minimal revenue ($16K) and substantial annual operating losses ($12M), resulting in a cash burn rate of $10.2M that depletes the $8.2M cash reserve in under one year. The company demonstrates no demonstrated business model, revenue generation capability, or clear path to profitability, making it fundamentally unsustainable at current operations without additional capital infusion.
Strengths
- Zero debt with clean capital structure
- Adequate short-term liquidity with 3.25x current ratio
- Strong cash position ($8.2M) relative to liabilities ($2.7M)
Risks
- Critical cash runway of <12 months at current $10.2M annual operating burn rate
- Virtually no revenue generation ($16K) with no demonstrated business model
- Extreme negative profitability margins (Operating Margin -74,856%, Net Margin -74,725%)
- High R&D intensity typical of biotech creates continued cash burn risk
- Dilution risk from future capital raises required for survival
Key Metrics to Watch
- Monthly operating cash burn rate and remaining cash runway
- Revenue growth and product pipeline advancement milestones
- Operating expense reduction or pivot to sustainable cost structure
Financial Metrics
Revenue
16.0K
Net Income
-12.0M
EPS (Diluted)
$-121.80
Free Cash Flow
-10.2M
Total Assets
8.7M
Cash
8.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-74,856.3%
Net Margin
-74,725.0%
ROE
-199.0%
ROA
-138.0%
FCF Margin
-63,681.3%
Balance Sheet & Liquidity
Current Ratio
3.25x
Quick Ratio
3.25x
Debt/Equity
0.00x
Debt/Assets
30.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T18:21:21.320888 |
Data as of: 2025-12-31 |
Powered by Claude AI